Is Calithera Biosciences Incorporated (NASDAQ:CALA)’s Fuel Running Low? Reports Show More Sellers

September 17, 2017 - By Clifton Ray

 Is Calithera Biosciences Incorporated (NASDAQ:CALA)’s Fuel Running Low? Reports Show More Sellers

Investors sentiment increased to 1.2 in Q4 2016. Its up 0.44, from 0.76 in 2016Q3. It increased, as 9 investors sold Calithera Biosciences Inc shares while 6 reduced holdings. 4 funds opened positions while 14 raised stakes. 5.98 million shares or 0.90% more from 5.92 million shares in 2016Q3 were reported.
462,878 are held by Vanguard Incorporated. Moreover, D E Shaw And Inc has 0% invested in Calithera Biosciences Inc (NASDAQ:CALA) for 77,592 shares. Howland Capital Mngmt Ltd Limited Liability Company, Massachusetts-based fund reported 12,000 shares. Adage Cap Prns Grp Llc reported 0.03% of its portfolio in Calithera Biosciences Inc (NASDAQ:CALA). Fmr Limited Liability Company invested 0% in Calithera Biosciences Inc (NASDAQ:CALA). Rbf Capital Limited Liability owns 13,000 shares or 0.01% of their US portfolio. Susquehanna Interest Gp Llp holds 74,569 shares. Blackrock Inv Mgmt Lc, New Jersey-based fund reported 2,467 shares. New York-based Millennium Mngmt Limited has invested 0% in Calithera Biosciences Inc (NASDAQ:CALA). First Eagle Invest Mngmt Ltd Llc owns 438,103 shares. Manufacturers Life Insur Com The, Ontario – Canada-based fund reported 108 shares. Moreover, Franklin Street Advsr Inc Nc has 0.07% invested in Calithera Biosciences Inc (NASDAQ:CALA). Connor Clark Lunn Investment Mngmt Limited has 0% invested in Calithera Biosciences Inc (NASDAQ:CALA) for 10,200 shares. Tfs Capital Limited Co has 28,408 shares for 0.02% of their portfolio. Blackrock Fund Advisors has invested 0% in Calithera Biosciences Inc (NASDAQ:CALA).

The stock of Calithera Biosciences Incorporated (NASDAQ:CALA) registered an increase of 0.03% in short interest. CALA’s total short interest was 2.92M shares in September as published by FINRA. Its up 0.03% from 2.92M shares, reported previously. With 386,200 shares average volume, it will take short sellers 8 days to cover their CALA’s short positions. The short interest to Calithera Biosciences Incorporated’s float is 22.25%.

The stock decreased 0.66% or $0.1 on September 15, reaching $15.05. About 1.01 million shares traded or 114.09% up from the average. Calithera Biosciences Inc (NASDAQ:CALA) has risen 278.82% since September 17, 2016 and is uptrending. It has outperformed by 262.12% the S&P500.

Calithera Biosciences, Inc. is a clinical-stage pharmaceutical company. The company has market cap of $533.92 million. The Firm focuses on discovering and developing small molecule drugs directed against tumor and immune cell targets that control key metabolic pathways in the tumor microenvironment. It currently has negative earnings. It is engaged in developing agents that take advantage of the metabolic requirements of tumor cells and cancer-fighting immune cells, such as cytotoxic T-cells.

Calithera Biosciences Inc (NASDAQ:CALA) Ratings Coverage

Among 4 analysts covering Calithera Biosciences (NASDAQ:CALA), 3 have Buy rating, 0 Sell and 1 Hold. Therefore 75% are positive. Calithera Biosciences had 8 analyst reports since July 24, 2015 according to SRatingsIntel. Citigroup upgraded the shares of CALA in report on Tuesday, January 24 to “Neutral” rating. The firm earned “Buy” rating on Friday, July 24 by Citigroup. The company was maintained on Wednesday, March 9 by JMP Securities. The rating was maintained by H.C. Wainwright on Monday, June 12 with “Buy”. The stock of Calithera Biosciences Inc (NASDAQ:CALA) has “Buy” rating given on Tuesday, March 28 by H.C. Wainwright. On Tuesday, October 25 the stock rating was initiated by Citigroup with “Sell”. H.C. Wainwright initiated Calithera Biosciences Inc (NASDAQ:CALA) rating on Thursday, January 5. H.C. Wainwright has “Buy” rating and $9 target.

More notable recent Calithera Biosciences Inc (NASDAQ:CALA) news were published by: Globenewswire.com which released: “Calithera Biosciences to Present at Cowen and Company 37th Annual Health Care …” on March 01, 2017, also Globenewswire.com with their article: “Calithera Biosciences Reports Second Quarter 2017 Financial Results and Recent …” published on August 08, 2017, Nasdaq.com published: “Earnings Estimates Moving Higher for Calithera Biosciences (CALA): Time to Buy?” on September 08, 2017. More interesting news about Calithera Biosciences Inc (NASDAQ:CALA) were released by: Globenewswire.com and their article: “Incyte and Calithera Biosciences Announce Global Collaboration to Develop and …” published on January 30, 2017 as well as Globenewswire.com‘s news article titled: “Calithera Biosciences to Participate in the Citi 12th Annual Biotech …” with publication date: August 30, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.